Adrienne G. Randolph, M.D., M.Sc., Associate Professor of Anaesthesia, Harvard Medical School and Senior Associate in Critical Care at Boston Children's Hospital, commented, "Acute Respiratory Failure is a major cause for the admission of children into the intensive care unit. There is a clear unmet medical need for better therapeutic options to help these children. A new medical therapy that reduces the duration of mechanical ventilation for patients with Acute Respiratory Failure would be considered clinically important."
Premature babies, or those that have passed meconium in utero depend on Sufraxin. It's either DSCO's drug or an animal derived alternative. Discovery owns this market segment. I expect quarter over quarter revenue growth year after year since there isn't an alternative.
I wonder if this has to do with getting Mass General up as a trial site? Fantastic news!
Another positive for Neuralstem.
One word - Daytraders. Serious investors however are accumulating shares, for they know what the future holds. So let the price fluctuate up and down 10% in a day, the trend higher is now established. Pay no attention to the amateurs.
Sure you could provide a large dose to non ambulatory patients, but the better route is to achieve approval by careful patient selection that maximizes CR and PFS.
Well, by the numbers there were 15 people in the Phase 1 trial. 1 appears to have shown a CR [complete response] (Ted Harada) - see stories online, and 5 appears to be demonstrating PR [partial response] and/or PFS [progression free survival]. That's a 40% PFS in ALS, which currently has no existing beneficial therapies. I suspect with the proper enrollment criteria they will see phase 2 results approaching 60-70% PFS. Should that happen the FDA would approve NSI-566 with just Phase 2 data given this is an Orphan Disease. CUR is significantly undervalued, marketcap on approval would easily exceed 1 Billion - 8x today's price.
Many large investors missed this one, and have been waiting for a pullback. How far back it goes, unclear, but "money" is waiting to enter. Retail investors won't miss this one twice. Choose your entry point accordingly.
Interesting time for PRAN. Certainly headed much higher.
Indeed it's excellent news for Astex. Unfortunately we just have a down day in the market, biotechs included. No worries though, I used it as a chance to buy additional shares at a discount. I feel even more confident doing so given the news. I expect some interesting price action next week.
When you can add a 3 month durable response benefit, to a heavily pretreated patient population who have relapsed, you call that a major success. SGI-110 looks very effective, and this is great news for the expansion trial.
Undervalued relative to revenue growth potential. Today's pullback makes it even more compelling. I also think they are at risk of being acquired by LIFE.
I've been wanting into GNMK for so long, but it never seemed to have a pullback. This is sweet! Thanks to whomever sold me shares.